Wedbush lowered the firm’s price target on Dianthus to $36 from $38 and keeps an Outperform rating on the shares. Most importantly in the company’s Q2 results, it was announced all development timelines remain on track, the analyst tells investors. The firm’s DNTH103 estimates remain unchanged and assume the earliest potential launch in FY28. The firm is also increasing its research and development expense ramp from FY24 forward to reflect the accelerating clinical trial efforts.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
- Dianthus initiated with an Outperform at Baird
- Two new option listings on July 9th
- Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
- Dianthus initiated with an Overweight at Cantor Fitzgerald
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue